A STUDY OF PLASMA NESFATIN-1 IN OBESE AND NON OBESE IN RELATION TO TYPE 2 DIABETES MELLITUS

Dr V Y Bhargav, Dr E Dhandapani

Abstract


The prevalence of metabolic disease is reaching pandemicproportions worldwide, of which obesity and diabetes are the primarydiseases of concern. In major cases of diabetes and obesity, the defects lie in glucose metabolism and energy homeostasis.

AIMS AND OBJECTIVES:

a)      Estimation and comparison of Plasma Nesfatin-1 in patients with Obesity and DM  with Normal individuals

b)      Estimation and comparison of plasma Nesfatin-1 levels in Obese and Non-obese individuals.

c)      Estimation and comparison of plasma Nesfatin-1 levels in Diabetic and Normal individuals

METHODS:

It is a hospital based prospective study of 80 patients, which is conducted at SREE BALAJI MEDICAL COLLEGE. The material for study is formed by adult patients admitted to General wards in our hospital between October 2017 to August 2018fulfilling the inclusion and exclusion criteria.

CONCLUSION:

In summary, our study demonstrated a significant lower values of plasmanesfatin-1 in obese individuals when compared to normal individuals and higher values in type2 diabetic individuals when compared to normal individuals


Keywords


obesity, diabetes, nesfatin-1

Full Text:

PDF

References


Scott, C.H.B.a.D.A., The Preparation of Insulin. Journal of Biological Chemistry, 1923. 57: p. 709723.

Halaas, J.L., et al., Weight-reducing effects of the plasma protein encoded by the obese gene. Science, 1995. 269(5223): p. 543-6.

Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002 Feb 28;122(2):531-44.

Gonzalez R, Reingold BK, Gao X, Gaidhu MP, Tsushima RG, Unniappan S. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β-and MIN6 cells. Journal of Endocrinology. 2011 Mar 1;208(3):R9-16.

Andersen, D.K., et al., Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels. J Clin Invest, 1978. 62(1): p. 15261.

Bottcher, G., et al., Peptide YY: intrapancreatic localization and effects on insulin and glucagon secretion in the mouse. Pancreas, 1989. 4(3): p. 282-8.

Holst, J.J., Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia, 2006. 49(2): p. 253-60.

Oh-I.S., et al., Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature, 2006. 443(7112): p. 709-12.

Foo, K.S., et al., Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol, 2010. 204(3): p. 255-63.

Li, Q.C., et al., Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept, 2010. 159(1-3): p. 72-7.


Refbacks

  • There are currently no refbacks.